Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat

Publication date: Available online 6 February 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Ziwei Li, Jun Zhang, Zhang Yufeng, Zuo ZhongAbstractSimvastatin is known as a pro-drug, which could be hydrolyzed by esterases to its active form, simvastatin acid. Although pharmacokinetics of simvastatin and simvastatin acid have been widely studied, hydrolysis of simvastatin to simvastatin acid during blood sampling and plasma preparation has been overlooked in the previous studies, leading to underestimation of simvastatin concentration and overestimation of simvastatin acid concentration in plasma. Since both efficacy and adverse drug reaction of simvastatin are highly dependent on simvastatin and simvastatin acid concentrations in vivo, accurate assessment of the two compounds are critical in their pharmacokinetic and pharmacodynamic studies. The current study was proposed aiming to investigate the esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on the pharmacokinetic study of simvastatin and simvastatin acid. Using various esterase inhibitors including potassium florid (KF), bis(4-nitrophenyl) phosphate (BNPP), and ethylenediaminetetraacetic acid (EDTA), carboxylesterase was found to be the major esterase that hydrolyzed simvastatin in rat blood, while carboxylesterase and paraoxonase were the major esterases mediating the hydrolysis of simvastatin in human blood. Further studies using human recombinant enzymes identifi...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research

Related Links:

After controversial guidelines were introduced, cholesterol levels are inching down and more Americans are taking much-needed statin drugs.
Source: Los Angeles Times - Science - Category: Science Authors: Source Type: news
CONCLUSION: Dyslipidemia patients with pre-existing depression had increased risk for CVD. Future studies that determine CVD risk after management of depression among dyslipidemia patients are needed. PMID: 31701694 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
The 2013 American College of Cardiology and American Heart Association practice guidelines recommend physicians prescribe HMG-CoA reductase inhibitors (statins) to patients with high cholesterol and to patients with or at high risk for atherosclerotic cardiovascular disease, regardless of cholesterol levels1. According to the National Center for Health Statistics (NCHS), from 2011 to 2012, 1 in 4 adults ages 40 years and older were taking prescription cholesterol lowering medications, 93% of which were statins2.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research
Conclusion: Early rule out protocol is effective and safe.We refer interested readers to the following excellent reviews of high-sensitivity troponin implementation:Twerenbold, R. et al.JACC70 (8): 996 –1012.https://doi.org/10.1016/j.jacc.2017.07.718.Yader S. et al. 2016. Am J Med 129 (4): 354 –65.https://doi.org/10.1016/j.amjmed.2015.12.005.Response to the 2nd “Myth-busting” articleInterestingly, on Nov 5, Dr. Spiegel publishedanother “Myths in EM” piece in EM News: “Is hs-cTnT Worth the Downstream Testing?. The piece assesses a new randomized trial of the Roche hs -cTnT...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study. PMID: 31694752 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week ’ s podcast.theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news
What have we learned about the effects of long-term statin therapy among this age group? Is it beneficial?Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGL...
Source: Cardiovascular Endocrinology - Category: Cardiology Tags: Review Articles Source Type: research
Conclusions. Our data suggests that hsa-miR-24-3p might have an effect on CYP4F2 activity during atherosclerosis. PMID: 31694408 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Evidence from observational studies have found a relationship between serum cholesterol and diabetic retinopathy (DR). Apart of the assumption that cholesterolemic control has benefits for patients with diabet...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Review Source Type: research
More News: Drugs & Pharmacology | Potassium | Simvastatin | Statin Therapy | Study | Zocor